Nutex Health Reports 82.4% Revenue Growth for Fiscal Year 2025
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy NUTX?
Source: Newsfilter
- Significant Revenue Growth: Nutex Health reported total revenue of $875.3 million for 2025, an 82.4% increase from $479.9 million in 2024, primarily driven by the hospital division's robust performance, which generated $844.2 million, up 188%.
- Net Income Improvement: The net income for 2025 was $70.8 million, an increase of $18.7 million from $52.1 million in 2024, reflecting a significant enhancement in the company's profitability and the effectiveness of its business model.
- Substantial EBITDA Increase: EBITDA for 2025 reached $168.6 million, a 70.6% increase from $98.8 million in 2024, while adjusted EBITDA soared to $259.6 million, up 152.6%, indicating improved operational efficiency.
- Strong Cash Flow: The net cash from operating activities for 2025 was $248.1 million, demonstrating ongoing improvements in cash management and operational efficiency, providing a solid financial foundation for future expansion and investments.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NUTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NUTX
Wall Street analysts forecast NUTX stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 108.440
Low
230.00
Averages
265.00
High
300.00
Current: 108.440
Low
230.00
Averages
265.00
High
300.00
About NUTX
Nutex Health Inc. is a healthcare management and operations company. The Company operates in three segments: the Hospital division, the Population Health Management (PHM) division, and the Real Estate division. The Hospital division owns, develops and operates healthcare models, including micro-hospitals, specialty hospitals, and hospital outpatient departments (HOPDs). This division owns and operates 24 facilities in 11 states. In addition, it has financial and operating relationships with multiple professional entities and real estate entities. The Population Health Management division owns and operates provider networks, such as Independent Physician Associations (IPAs). Through its Management Services Organization (MSO), it provides management, administrative and other support services to its affiliated hospitals and physician groups. The Real Estate division comprises the Real Estate Entities, which owns the land and hospital buildings which are leased to its hospital entities.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Nutex Health Reports 82.4% Revenue Growth for Fiscal Year 2025
- Significant Revenue Growth: Nutex Health reported total revenue of $875.3 million for 2025, an 82.4% increase from $479.9 million in 2024, primarily driven by the hospital division's robust performance, which generated $844.2 million, up 188%.
- Net Income Improvement: The net income for 2025 was $70.8 million, an increase of $18.7 million from $52.1 million in 2024, reflecting a significant enhancement in the company's profitability and the effectiveness of its business model.
- Substantial EBITDA Increase: EBITDA for 2025 reached $168.6 million, a 70.6% increase from $98.8 million in 2024, while adjusted EBITDA soared to $259.6 million, up 152.6%, indicating improved operational efficiency.
- Strong Cash Flow: The net cash from operating activities for 2025 was $248.1 million, demonstrating ongoing improvements in cash management and operational efficiency, providing a solid financial foundation for future expansion and investments.
See More
Nutex Health Reports Strong Financial Results for Fiscal Year 2025
- Significant Revenue Growth: Nutex Health achieved an impressive 82% revenue growth in fiscal year 2025, with total revenue reaching $875.3 million, indicating strong demand and market expansion capabilities in the healthcare services sector.
- Adjusted EBITDA Surge: The company reported an Adjusted EBITDA of $259.6 million, a remarkable 126.4% increase, demonstrating significant progress in operational efficiency and cost control, thereby enhancing future profitability.
- Strong Cash Position: As of December 31, 2025, Nutex Health's cash and cash equivalents stood at $185.6 million, a substantial increase from 2024, providing ample financial support for future expansions and investments.
- Stock Repurchase Program: The Board of Directors has authorized a stock repurchase program of up to $25 million, aimed at enhancing shareholder value and offsetting future dilution, reflecting the company's confidence in its stock value.
See More
Nutex Health to Announce Q4 Earnings on March 5
- Earnings Announcement Schedule: Nutex Health is set to release its Q4 earnings report on March 5 after market close, with consensus EPS estimates at $5.56 and revenue projected at $258.82 million, reflecting a modest 0.5% year-over-year growth, which will provide investors with insights into the company's financial health.
- Receivables Challenge: The company is grappling with a significant $387 million receivables issue, which could impact its cash flow and operational flexibility, prompting investors to monitor how Nutex addresses this challenge to sustain its growth trajectory.
- Growth vs. Sustainability: While Nutex Health demonstrates strong growth potential, there are lingering doubts about its long-term sustainability, particularly in light of the receivables problem, necessitating a careful assessment of the risks to its future profitability.
- Market Reaction Anticipation: As the earnings report approaches, market reactions to Nutex Health will be influenced by its financial data and management's outlook, making it crucial for investors to closely watch the upcoming report to gauge potential stock price movements.
See More
Nutex Health to Release 2025 Annual Report
- Earnings Report Plan: Nutex Health plans to file its Form 10-K for the fiscal year ending December 31, 2025, on March 5, 2026, after market close, accompanied by a press release summarizing financial results to enhance investor transparency.
- Conference Call Details: The company will host an earnings conference call on March 6, 2026, at 9:30 AM CT to discuss financial performance and provide a business update, which is expected to attract attention from investors and analysts alike.
- Company Overview: Founded in 2011 and headquartered in Houston, Texas, Nutex Health operates 27 micro hospitals and outpatient departments across 12 states, focusing on innovative healthcare delivery models to enhance patient care.
- Risk Factors Disclosure: The press release highlights that future performance may be affected by various known and unknown risks, including management capabilities, lack of capital, and industry competition, urging investors to consider potential uncertainties.
See More
Nutex Health to Release Annual Report on March 5, 2026
- Earnings Report Schedule: Nutex Health plans to file its Form 10-K for the fiscal year ending December 31, 2025, on March 5, 2026, after market close, which is expected to significantly impact investor sentiment.
- Conference Call Details: The company will host an earnings conference call on March 6, 2026, at 9:30 a.m. CT to discuss financial performance and provide business updates, enhancing communication with investors.
- Company Overview: Founded in 2011 and headquartered in Houston, Texas, Nutex Health operates 27 micro hospitals and outpatient departments across 12 states, showcasing its innovative capabilities in healthcare management.
- Risk Factors Disclosure: The press release includes forward-looking statements indicating that future performance may be affected by various known and unknown risks, highlighting the importance of management's ability to respond to rapid growth and market demands.
See More
Iovance and Others Face Shareholder Lawsuits Seeking Governance Reforms
- Shareholder Lawsuit Background: Iovance Biotherapeutics is facing a securities class action lawsuit from shareholders alleging that it failed to disclose significant misleading information regarding the commercial demand and revenue potential of its lead therapy, Amtagvi, resulting in investor losses.
- Governance Reform Opportunity: Shareholders who held Iovance shares continuously since before May 9, 2024, may seek governance reforms related to internal controls, transparency, and executive oversight, with successful claimants potentially eligible for incentive awards subject to court approval.
- Nutex Health Allegations: Nutex Health is similarly facing shareholder lawsuits, accused of overstating revenue from arbitration-related claims and failing to disclose material weaknesses in internal accounting controls, which led to financial results not being prepared in accordance with GAAP, impacting investor confidence.
- Molina Healthcare Issues: Molina Healthcare has also been accused of making misleading statements regarding medical cost trends and financial outlook, failing to disclose that medical cost pressures were materially higher than represented, potentially leading to governance reform opportunities for its shareholders.
See More
Nutex Health Reports 82.4% Revenue Growth for Fiscal Year 2025
- Significant Revenue Growth: Nutex Health reported total revenue of $875.3 million for 2025, an 82.4% increase from $479.9 million in 2024, primarily driven by the hospital division's robust performance, which generated $844.2 million, up 188%.
- Net Income Improvement: The net income for 2025 was $70.8 million, an increase of $18.7 million from $52.1 million in 2024, reflecting a significant enhancement in the company's profitability and the effectiveness of its business model.
- Substantial EBITDA Increase: EBITDA for 2025 reached $168.6 million, a 70.6% increase from $98.8 million in 2024, while adjusted EBITDA soared to $259.6 million, up 152.6%, indicating improved operational efficiency.
- Strong Cash Flow: The net cash from operating activities for 2025 was $248.1 million, demonstrating ongoing improvements in cash management and operational efficiency, providing a solid financial foundation for future expansion and investments.
See More
Nutex Health Reports Strong Financial Results for Fiscal Year 2025
- Significant Revenue Growth: Nutex Health achieved an impressive 82% revenue growth in fiscal year 2025, with total revenue reaching $875.3 million, indicating strong demand and market expansion capabilities in the healthcare services sector.
- Adjusted EBITDA Surge: The company reported an Adjusted EBITDA of $259.6 million, a remarkable 126.4% increase, demonstrating significant progress in operational efficiency and cost control, thereby enhancing future profitability.
- Strong Cash Position: As of December 31, 2025, Nutex Health's cash and cash equivalents stood at $185.6 million, a substantial increase from 2024, providing ample financial support for future expansions and investments.
- Stock Repurchase Program: The Board of Directors has authorized a stock repurchase program of up to $25 million, aimed at enhancing shareholder value and offsetting future dilution, reflecting the company's confidence in its stock value.
See More
Nutex Health to Announce Q4 Earnings on March 5
- Earnings Announcement Schedule: Nutex Health is set to release its Q4 earnings report on March 5 after market close, with consensus EPS estimates at $5.56 and revenue projected at $258.82 million, reflecting a modest 0.5% year-over-year growth, which will provide investors with insights into the company's financial health.
- Receivables Challenge: The company is grappling with a significant $387 million receivables issue, which could impact its cash flow and operational flexibility, prompting investors to monitor how Nutex addresses this challenge to sustain its growth trajectory.
- Growth vs. Sustainability: While Nutex Health demonstrates strong growth potential, there are lingering doubts about its long-term sustainability, particularly in light of the receivables problem, necessitating a careful assessment of the risks to its future profitability.
- Market Reaction Anticipation: As the earnings report approaches, market reactions to Nutex Health will be influenced by its financial data and management's outlook, making it crucial for investors to closely watch the upcoming report to gauge potential stock price movements.
See More
Nutex Health to Release 2025 Annual Report
- Earnings Report Plan: Nutex Health plans to file its Form 10-K for the fiscal year ending December 31, 2025, on March 5, 2026, after market close, accompanied by a press release summarizing financial results to enhance investor transparency.
- Conference Call Details: The company will host an earnings conference call on March 6, 2026, at 9:30 AM CT to discuss financial performance and provide a business update, which is expected to attract attention from investors and analysts alike.
- Company Overview: Founded in 2011 and headquartered in Houston, Texas, Nutex Health operates 27 micro hospitals and outpatient departments across 12 states, focusing on innovative healthcare delivery models to enhance patient care.
- Risk Factors Disclosure: The press release highlights that future performance may be affected by various known and unknown risks, including management capabilities, lack of capital, and industry competition, urging investors to consider potential uncertainties.
See More
Nutex Health to Release Annual Report on March 5, 2026
- Earnings Report Schedule: Nutex Health plans to file its Form 10-K for the fiscal year ending December 31, 2025, on March 5, 2026, after market close, which is expected to significantly impact investor sentiment.
- Conference Call Details: The company will host an earnings conference call on March 6, 2026, at 9:30 a.m. CT to discuss financial performance and provide business updates, enhancing communication with investors.
- Company Overview: Founded in 2011 and headquartered in Houston, Texas, Nutex Health operates 27 micro hospitals and outpatient departments across 12 states, showcasing its innovative capabilities in healthcare management.
- Risk Factors Disclosure: The press release includes forward-looking statements indicating that future performance may be affected by various known and unknown risks, highlighting the importance of management's ability to respond to rapid growth and market demands.
See More
Iovance and Others Face Shareholder Lawsuits Seeking Governance Reforms
- Shareholder Lawsuit Background: Iovance Biotherapeutics is facing a securities class action lawsuit from shareholders alleging that it failed to disclose significant misleading information regarding the commercial demand and revenue potential of its lead therapy, Amtagvi, resulting in investor losses.
- Governance Reform Opportunity: Shareholders who held Iovance shares continuously since before May 9, 2024, may seek governance reforms related to internal controls, transparency, and executive oversight, with successful claimants potentially eligible for incentive awards subject to court approval.
- Nutex Health Allegations: Nutex Health is similarly facing shareholder lawsuits, accused of overstating revenue from arbitration-related claims and failing to disclose material weaknesses in internal accounting controls, which led to financial results not being prepared in accordance with GAAP, impacting investor confidence.
- Molina Healthcare Issues: Molina Healthcare has also been accused of making misleading statements regarding medical cost trends and financial outlook, failing to disclose that medical cost pressures were materially higher than represented, potentially leading to governance reform opportunities for its shareholders.
See More
